CCR5 Receptor Antagonists

Compounds and drugs that inhibit or block the activity of CCR5 RECEPTORS.

Also Known As:

CC Chemokine Receptor 5 Antagonists; CC Chemokine Receptor 5 Blockers; CCR5 Receptor Blockers; Chemokine Co-receptor 5 Antagonists; HIV-1 Fusion Coreceptor Antagonists; Antagonists, CCR5 Receptor; Blockers, CCR5 Receptor; Chemokine Co receptor 5 Antagonists; HIV 1 Fusion Coreceptor Antagonists; Receptor Antagonists, CCR5; Receptor Blockers, CCR5

Networked: 6 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Therapeutic Uses: 47080
    - Anti-Infective Agents: 8032
      - Antiviral Agents: 47706
        Anti-Retroviral Agents: 656
        Anti-HIV Agents: 514
        CCR5 Receptor Antagonists: 6
  - Molecular Mechanisms of Pharmacological Action: 24
    - CCR5 Receptor Antagonists: 6

Experts

1.	Borges, S: 1 article (05/2016)
2.	Hendershot, S: 1 article (05/2016)
3.	Hesk, D: 1 article (05/2016)
4.	Koharski, D: 1 article (05/2016)
5.	McNamara, P: 1 article (05/2016)
6.	Ren, S: 1 article (05/2016)
7.	Saluja, S: 1 article (05/2016)
8.	Truong, V: 1 article (05/2016)
9.	Voronin, K: 1 article (05/2016)
10.	Addya, Sankar: 1 article (12/2014)

Related Diseases

1.	HIV Infections (HIV Infection) 07/01/2006 - "The discovery of CCR5 receptor antagonists for the treatment of HIV infection: hit-to-lead studies." 05/15/2016 - "CCR5 receptor antagonists have the potential for the treatment of HIV infections. " 03/01/2002 - "The company has continued to investigate a number of second-generation CCR5 receptor antagonists, including Sch-350634, for the potential treatment of HIV infection. " 09/01/2010 - "Modification of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists revealed that introducing a fluoro group at the 3-position of the 3-phenyl group to reduce metabolism did not adversely affect the high potency against HIV infection, and that replacing the piperidine ring with a tropane ring could deliver the most potent anti-HIV agents. "
2.	Prostatic Neoplasms (Prostate Cancer) 12/01/2014 - "CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines."
3.	Neoplasm Metastasis (Metastasis) 12/01/2014 - "CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines."
4.	Infections 12/01/2012 - "Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers."

Related Drugs and Biologics

1.	Anti-HIV Agents (AIDS Drugs)
2.	1- ((2,4- dimethyl- 3- pyridinyl)carbonyl)- 4- methyl- 4- (3- methyl- 4- (1- (4- (trifluoromethyl)phenyl)ethyl)- 1- piperazinyl)piperidine N1-oxide
3.	piperidine
4.	pyrrolidine